599 related articles for article (PubMed ID: 19579592)
1. Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis C patients by interferon-beta-1a with or without sustained viral response.
Rao HY; Wei L; Li J; Zhang LF; Chen HY; Zhu LM; Liu F; Sun Y; Wang H
Hepatogastroenterology; 2009; 56(90):328-34. PubMed ID: 19579592
[TBL] [Abstract][Full Text] [Related]
2. [Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].
Rao HY; Li J; Zhang LF; Chen HY; Zhu LM; Wei L; Sun Y; Wang H
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):96-100. PubMed ID: 18353212
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy.
Sakaida I; Nagatomi A; Hironaka K; Uchida K; Okita K
Am J Gastroenterol; 1999 Feb; 94(2):489-96. PubMed ID: 10022652
[TBL] [Abstract][Full Text] [Related]
4. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of combination therapy with interferon-alpha and ribavirin for chronic hepatitis C in relation to liver fibrosis and serum aminotransferase activity].
Karpińska E; Wawrzynowicz-Syczewska M; Jurczyk K; Morańska I; Urbanowicz W; Boroń-Kaczmarska A
Wiad Lek; 2005; 58(11-12):616-21. PubMed ID: 16594470
[TBL] [Abstract][Full Text] [Related]
7. Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C.
Ueno T; Inuzuka S; Sata M; Koh H; Tamaki S; Kin M; Sugawara H; Sakata R; Torimura T; Tanikawa K
Hepatogastroenterology; 1995; 42(5):522-7. PubMed ID: 8751209
[TBL] [Abstract][Full Text] [Related]
8. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation.
Carpino G; Morini S; Ginanni Corradini S; Franchitto A; Merli M; Siciliano M; Gentili F; Onetti Muda A; Berloco P; Rossi M; Attili AF; Gaudio E
Dig Liver Dis; 2005 May; 37(5):349-56. PubMed ID: 15843085
[TBL] [Abstract][Full Text] [Related]
9. Hepatic alpha-smooth muscle actin expression in hepatitis C patients before and after interferon therapy.
Khan MA; Poulos JE; Brunt EM; Li L; Solomon H; Britton RS; Bacon BR; Di Bisceglie AM
Hepatogastroenterology; 2001; 48(37):212-5. PubMed ID: 11268968
[TBL] [Abstract][Full Text] [Related]
10. Assessment of selected clinical factors as predictors of response to combined interferon-alpha plus ribavirin therapy among patients with chronic hepatitis C.
Kryczka W; Zarebska-Michaluk D; Chrapek M
Med Sci Monit; 2003 Aug; 9 Suppl 3():32-5. PubMed ID: 15156609
[TBL] [Abstract][Full Text] [Related]
11. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection.
Muir AJ; Sylvestre PB; Rockey DC
J Viral Hepat; 2006 May; 13(5):322-8. PubMed ID: 16637863
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin.
Trocme C; Leroy V; Sturm N; Hilleret MN; Bottari S; Morel F; Zarski JP
J Viral Hepat; 2006 Oct; 13(10):643-51. PubMed ID: 16970595
[TBL] [Abstract][Full Text] [Related]
13. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
Bani-Sadr F; Lapidus N; Bedossa P; De Boever CM; Perronne C; Halfon P; Pol S; Carrat F; Cacoub P; ;
Clin Infect Dis; 2008 Mar; 46(5):768-74. PubMed ID: 18248298
[TBL] [Abstract][Full Text] [Related]
14. [Serum markers and pathological evaluation in hepatitis fibrosis of chronic hepatitis B treated with interferon alpha].
Deng L; Zhou Y; Peng X; Deng H; Deng Y; Yao J
Zhonghua Gan Zang Bing Za Zhi; 2001 Jul; 9 Suppl():66-7. PubMed ID: 11509145
[TBL] [Abstract][Full Text] [Related]
15. [Interferon-alpha and liver fibrosis in patients with chronic damage due to hepatitis C virus].
Gonzalez-Huezo MS; Gallegos-Orozco JF
Rev Gastroenterol Mex; 2003; 68(3):239-44. PubMed ID: 14702938
[TBL] [Abstract][Full Text] [Related]
16. State of the iron metabolism in patients with chronic hepatitis C type C does not influence antiviral treatment with interferon and ribavirin.
Jurczyk K; Karpińska E; Wawrzynowicz-Syczewska M; Morańska I; Noceń I; Chlubek D; Boroń-Kaczmarska A
Hepatogastroenterology; 2008; 55(82-83):557-61. PubMed ID: 18613407
[TBL] [Abstract][Full Text] [Related]
17. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.
Huang JF; Yu ML; Lee CM; Dai CY; Hou NJ; Hsieh MY; Wang JH; Lu SN; Sheen IS; Lin SM; Chuang WL; Liaw YF
Aliment Pharmacol Ther; 2007 May; 25(9):1029-37. PubMed ID: 17439503
[TBL] [Abstract][Full Text] [Related]
18. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy.
Taniguchi H; Iwasaki Y; Fujiwara A; Sakaguchi K; Moriya A; Yu PC; Takaki A; Fujioka S; Shimomura H; Shiratori Y
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):281-7. PubMed ID: 16460487
[TBL] [Abstract][Full Text] [Related]
19. Additive therapeutic effects of the liver extract preparation mixture adelavin-9 on interferon-beta treatment for chronic hepatitis C.
Ebinuma H; Saito H; Tada S; Masuda T; Kamiya T; Nishida J; Yoshioka M; Ishii H;
Hepatogastroenterology; 2004; 51(58):1109-14. PubMed ID: 15239256
[TBL] [Abstract][Full Text] [Related]
20. [Experiences with the treatment of chronic hepatitis C and prognostic factors for its efficacy in clinical practice].
Kristian P; Schréter I; Paralicová Z; Jarcuska P; Pellová A; Magyar B; Virág L
Klin Mikrobiol Infekc Lek; 2010 Aug; 16(4):139-44. PubMed ID: 20809465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
